I have over 20 years of experience in life sciences cross-functional planning, drug development strategy and program leadership, and strategic scientific and investor communications. My specialty is identifying and clearly articulating the key focus - the critical components of a portfolio plan, a development program, or a complex scientific story. Once the focus is clear, I break down the steps to get there and work with teams to develop efficient, effective plans and communications.
When every moment and every dollar counts, you need accurate, robust, realistic and creative plans for your development-stage assets.
I have extensive experience creating and refining development plans for key assets ranging from discovery stage through clinical trials and registration, with risk assessments and key inflection and investment points.
I can establish or re-align Program Teams to ensure clear cross-functional communication, collaboration, decision making, and accurate identification of dependencies.
Realistic assessments of development needs across a portfolio of assets and clear scenario plans guide your strategic investment and prioritization decisions.
Particular expertise in integrating planning across Research, Development, and CMC for first-in-class gene therapies
Compelling scientific storytelling is the key to conveying your science and your company's value to investors, collaborators, physicians and patients.
My deep experience in creating accessible explanations of innovative science and combining them with clear and compelling illustrations of serious unmet medical and social needs enables you to tell your story.
I deliver investor decks, website content, press releases, and comprehensive strategic communications packages that clearly capture the promise of the science in ways that are tailored to key audiences and consistent with corporate values and branding.
I enable early-stage companies to ensure that storytelling for research audiences, advocacy groups, and investors are fully aligned.
Limited, complex data that may be difficult to understand mean that effective scientific communications are key to your company's success.
I have spearheaded and independently developed pre-clinical and phase 1-3 clinical publications for major venues such as NEJM, Nature Medicine, ASH, and ASGCT.
I ensure swift, smooth development of critical publications with minimal burden on company staff who are focused on furthering research or fundraising.
Excellent design and attention to detail mean that your conference presentation, poster, or journal article will represent both your science and your company in the most effective and confidence-inspiring manner.